Longeveron Chief Science Officer Dr. Joshua Hare To Keynote 2018 HEALinc Future Health Innovation Summit
MIAMI /PRNewswire/ -- Longeveron, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chief Science Officer Joshua Hare, M.D. will be a keynote speaker at the 2018 HEALinc Future Health Innovation Summit, to be held Oct. 7-9 at the Melia Nassau Beach Hotel, Nassau, Bahamas.
The inaugural annual event will bring together renowned researchers, clinicians, entrepreneurs, investors and regulators to discuss cutting-edge advancements in regenerative medicine, cellular therapy and emerging healthcare technologies. Dr. Hare also will be presented with a special lifetime achievement award for his pioneering work in stem cell research.
"I am very pleased to be taking part in this first Bahamas HEALinc summit in collaboration with the leading industry experts and innovators who are now working on new therapies that will herald the future of regenerative medicine. The Bahamas is an ideal venue for this summit as it has enacted progressive legislation – with significant regulatory oversight by the National Stem Cell Ethics Committee under the leadership of Dr. Desiree Cox - that recognizes and fosters the great value of regenerative medicine," Dr. Hare said.
Longeveron's Mesenchymal Stem Cell product is derived from the bone marrow of young, healthy adult donors and is manufactured in its Current Good Manufacturing Practice (CGMP) facility in Miami, Florida. Longeveron is researching treatments based on its allogeneic Mesenchymal Stem Cells for a variety of diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty. The company is now recruiting for an expanded Phase 2b Aging Frailty study, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. In addition, Longeveron is recruiting for a Phase 1 Alzheimer's trial.
Longeveron's MSCs are also approved for use in the Bahamas. As the only company to have a locally-approved allogeneic stem cell treatment, Longeveron currently is conducting a single-arm open label clinical trial for Aging Frailty in the Bahamas and is planning to add other indications to its Bahamas trial including cognitive disorders and orthopedic conditions.
SOURCE Longeveron LLC